Aqualung Therapeutic’s ALT-100 Antibody Significantly Reduces ARDS Severity in Both Rat and Porcine (Large Animal) Preclinical Models

TUCSON, AZ / ACCESSWIRE / February 1, 2022 / Aqualung Therapeutics, an early-stage immunotherapeutics biotech company developing an anti-inflammatory therapeutic platform for unchecked inflammation, a characteristic of serious acute diseases; has published a study in Scientific Reports (Tadeo Bermudez lead author) highlighting the effectiveness of the eNAMPT-neutralizing ALT-100 monoclonal antibody (mAb)in reducing Acute Respiratory Distress Syndrome (ARDS)/Ventilator Induced Lung Injury (VILI) symptoms in both rat and porcine animal models.
Continue reading

C-Path and the European Joint Programme on Rare Diseases to Expand Global Impact and Partnership

PARIS, France and TUCSON, Ariz., U.S., February 1, 2022 — Critical Path Institute (C-Path), an independent global nonprofit organization, and the European Joint Programme on Rare Diseases (EJP RD), an initiative that has received funding from the European Union’s Horizon 2020 research and innovation programme, have announced a collaboration to advance technologies and methodologies that are fit for regulatory purposes to further global rare disease research and drug development.Continue reading

Preclinical studies show Aqualung Therapeutic’s eNAMPT- targeting ALT-100 mAb to reduce severity of aggressive prostate cancer

Preclinical prostate cancer (PCa] studies published in the December 17th, 2021 issue of Pharmaceuticals show Aqualung Therapeutic’s ALT-100 mAb to significantly improve overall survival and to reduce distal metastases in SCID mice implanted with human prostate cancer (PCa] cells. Aqualung Therapeutics is an early stage immunotherapeutics company with an anti-inflammatory therapeutic platform to address life-threatening unchecked inflammation.

Continue reading

Arizona State University Biodesign Institute receives three new grants totaling $5.2 million to advance the fight against Parkinson’s disease

The Michael J. Fox Foundation has awarded three new grants totaling $5.2 million to Arizona State University (ASU) to explore three pioneering treatments for Parkinson’s disease (PD).

The awards will fund research led by Principal Investigator Dr. Jeffrey H. Kordower, each targeting underlying causes of the disease, which currently affects nearly 1 million people in the U.S. alone.

The new projects focus on two primary hallmarks of PD: the loss of dopamine-producing neurons in the brain and the accumulation within nerve cells of a misfolded form of the protein alpha-synuclein (α-syn).

Continue reading

Preparing to deliver next-generation therapeutics

Mayo Clinic is among the academic medical centers on the cusp of biomanufacturing next-generation cell and gene therapies that offer hope of new cures for rare and complex diseases. Biomanufacturing this new era of biologic medicines is much different than manufacturing pharmaceuticals from complex molecules. It requires highly specialized lab infrastructure, new processes and new scientific know-how.

A couple of Mayo Clinic-led papers encompass some of the first studies to probe how hospital facilities are handling the growing demand for cell and gene therapies that are being tested in clinical trials.Continue reading

Aqualung Therapeutics Corp., an Immunotherapeutics Biotech Company, Closes a $2.5M Convertible Note Raise With a Committed Series A Lead Investor

TUCSON, AZ / ACCESSWIRE / January 18, 2022 / Aqualung Therapeutics, an early stage immunotherapeutics company with an anti-inflammatory therapeutic platform for life-threatening unchecked inflammation, has closed a $2.5M convertible note fund raise led by a $1.5M investment from JSR Life Sciences, LLC. The convertible note close brings the total Aqualung funding to date to >$17M, with $14 million derived from non-dilutive capital via NIH-funded grants and an earlier successfully executed $700,000 early seed round. In addition to investments in the convertible note, JSR Life Sciences has committed an additional $1.5M to the upcoming $10M Series A capital raise.Continue reading